Analysts expect Halozyme Therapeutics, Inc. (NASDAQ:HALO) to announce ($0.13) earnings per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Halozyme Therapeutics’ earnings, with estimates ranging from ($0.19) to ($0.05). Halozyme Therapeutics reported earnings of ($0.19) per share during the same quarter last year, which would indicate a positive year over year growth rate of 31.6%. The firm is expected to issue its next earnings results on Tuesday, November 5th.
On average, analysts expect that Halozyme Therapeutics will report full-year earnings of ($0.35) per share for the current year, with EPS estimates ranging from ($0.42) to ($0.23). For the next fiscal year, analysts forecast that the company will post earnings of ($0.48) per share, with EPS estimates ranging from ($0.81) to ($0.23). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that follow Halozyme Therapeutics.
Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.10) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.17) by $0.07. Halozyme Therapeutics had a negative net margin of 23.53% and a negative return on equity of 16.97%. The business had revenue of $39.10 million during the quarter, compared to analysts’ expectations of $42.94 million. During the same quarter in the prior year, the company earned ($0.16) EPS. The firm’s quarterly revenue was up 11.1% on a year-over-year basis.
Shares of HALO traded up $0.33 during trading hours on Wednesday, reaching $16.61. The stock had a trading volume of 19,487 shares, compared to its average volume of 805,187. The company has a quick ratio of 2.57, a current ratio of 2.89 and a debt-to-equity ratio of 0.05. Halozyme Therapeutics has a 52 week low of $13.24 and a 52 week high of $18.85. The firm has a 50-day moving average of $16.77 and a 200 day moving average of $16.37. The company has a market cap of $2.32 billion, a P/E ratio of -29.66 and a beta of 1.76.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. NumerixS Investment Technologies Inc boosted its stake in Halozyme Therapeutics by 70.7% in the 2nd quarter. NumerixS Investment Technologies Inc now owns 2,390 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 990 shares during the period. Steward Partners Investment Advisory LLC acquired a new position in Halozyme Therapeutics in the 2nd quarter worth $49,000. Ladenburg Thalmann Financial Services Inc. boosted its stake in Halozyme Therapeutics by 25.2% in the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,800 shares of the biopharmaceutical company’s stock worth $83,000 after purchasing an additional 967 shares during the period. Quantamental Technologies LLC acquired a new position in Halozyme Therapeutics in the 2nd quarter worth $173,000. Finally, CWM Advisors LLC acquired a new position in Halozyme Therapeutics in the 2nd quarter worth $175,000. 79.98% of the stock is owned by hedge funds and other institutional investors.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.
Recommended Story: What is a stock buyback?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.